Studio City International Holdings Down 6% Since Q2 Release

Studio City International Holdings Limited (NYSE:MSC) reported a 6% decline in stock price since its Q2 2025 release. Despite a year-over-year increase in revenue and operating income, the company posted $190.1 million in quarterly operating revenue, up from $161.5 million last year. The casino's gross gaming revenue increased to $359.6 million, and non-gaming revenue reached $106.3 million. However, management attributed the operating income jump to strategic repositioning and better market performance.

Studio City International Holdings Limited (NYSE: MSC) experienced a 6% decline in its stock price since the release of its Q2 2025 financial results. The company reported a year-over-year increase in revenue and operating income, with quarterly operating revenue reaching $190.1 million, up from $161.5 million in the same period last year. Gross gaming revenue at the casino increased to $359.6 million, while non-gaming revenue reached $106.3 million.

Despite these positive financial indicators, the company's stock price has fallen. Management attributed the operating income jump to strategic repositioning and better market performance. The company's debt-to-equity ratio is 3.62, indicating potential financial strain. However, Invesco Ltd. recently acquired 25,000 shares of Studio City Ih stock, valued at around $141,000, suggesting institutional interest despite the stock's decline [1].

The stock's 50-day simple moving average is $4.12, and the 200-day simple moving average is $3.66. The company has a market capitalization of $951.40 million and a price-to-earnings ratio of -12.90. The stock's beta of -0.08 indicates low volatility compared to the broader market.

Studio City Ih's share price was down 6.4% on Monday, trading as low as $4.48 and last trading at $4.32. Approximately 945 shares changed hands during trading, a decline of 89% from the average daily volume of 8,869 shares. The stock had previously closed at $4.61 [1].

While the company's Q2 2025 results show growth in key financial metrics, the stock's recent decline suggests that investors are cautious about the company's financial health and potential future performance. The company's debt-to-equity ratio and the recent institutional investment by Invesco Ltd. may provide some reassurance, but the stock's price decline indicates that investors are still uncertain about the company's long-term prospects.

References:
[1] https://www.marketbeat.com/instant-alerts/studio-city-ih-nysemsc-stock-price-down-64-time-to-sell-2025-08-18/
[2] https://www.ainvest.com/news/market-moves-tjx-guess-rocket-pharmaceuticals-stocks-rise-earnings-fda-developments-2508/